{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:34:45Z","timestamp":1790087685943,"version":"4.0.1"},"reference-count":44,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2024,2,13]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Cellular senescence has been associated with neurodegenerative disease and clearance of senescent cells using genetic or pharmaceutical strategies (senolytics) has demonstrated beneficial effects in mouse models investigating individual disease etiologies of Alzheimer\u2019s disease (AD). However, it has remained unclear if senescent cell clearance in a mouse model exhibiting both plaque and tau pathologies modifies the disease state (3xTg).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To investigate the effects of senescent cell clearance in the 3xTg mouse model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>3xTg mice were treated with senolytics (ABT263 (navitoclax; NAVI), a combination of dasatinib and quercetin (D+Q)), or subjected to transgene-mediated removal of p16-expressing cells (via INK-ATTAC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Senolytic treatments consistently reduced microgliosis and ameliorated both amyloid and tau pathology in 3xTg mice. Using RNA sequencing, we found evidence that synaptic dysfunction and neuroinflammation were attenuated with treatment. These beneficial effects were not observed with short-term senolytic treatment in mice with more advanced disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Overall, our results further corroborate the beneficial effects senescent cell clearance could have on AD and highlight the importance of early intervention for the treatment of this debilitating disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3233\/jad-230465","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T11:58:37Z","timestamp":1706615917000},"page":"1751-1763","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":34,"title":["Senescence Targeting Methods Impact Alzheimer\u2019s Disease Features in 3xTg Mice"],"prefix":"10.1177","volume":"97","author":[{"given":"Pei Y.","family":"Ng","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA"},{"name":"Paul F. Glenn Center for Biology of Aging Research, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA"},{"name":"Paul F. Glenn Center for Biology of Aging Research, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren J.","family":"Baker","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA"},{"name":"Paul F. Glenn Center for Biology of Aging Research, Mayo Clinic, Rochester, MN, USA"},{"name":"The Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, USA"},{"name":"Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"key":"ref001","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00269-y"},{"key":"ref002","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-015-0232-5"},{"key":"ref003","unstructured":"United Nations (2022) World Population Prospects. https:\/\/population.un.org\/wpp, Last updated 2022, Accessed on March 8, 2023."},{"key":"ref004","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0543-y"},{"key":"ref005","first-page":"780","volume":"72","author":"Xu M","year":"2017","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"ref006","doi-asserted-by":"publisher","DOI":"10.1038\/nature10600"},{"key":"ref007","doi-asserted-by":"publisher","DOI":"10.1038\/nature16932"},{"key":"ref008","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23041989"},{"key":"ref009","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12840"},{"key":"ref010","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-019-0372-9"},{"key":"ref011","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2011226118"},{"key":"ref012","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109228"},{"key":"ref013","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(03)00434-3"},{"key":"ref014","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12873"},{"key":"ref015","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080355"},{"key":"ref016","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bts635"},{"key":"ref017","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkt214"},{"key":"ref018","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8"},{"key":"ref019","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506580102"},{"key":"ref020","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12445"},{"key":"ref021","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12344"},{"key":"ref022","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-201014"},{"key":"ref023","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2010.10.009"},{"key":"ref024","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.785276"},{"key":"ref025","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-200000001-00008"},{"key":"ref026","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2007.01.010"},{"key":"ref027","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4440-12.2013"},{"key":"ref028","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2020.00198"},{"key":"ref029","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.1994.tb00838.x"},{"key":"ref030","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2015.00084"},{"key":"ref031","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-190484"},{"key":"ref032","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201797397"},{"key":"ref033","first-page":"191","volume-title":"Handbook of Clinical Neurology","author":"Shekari A","year":"2021"},{"key":"ref034","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.5620-07.2008"},{"key":"ref035","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218144"},{"key":"ref036","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32552-1"},{"key":"ref037","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-022-00531-5"},{"key":"ref038","doi-asserted-by":"publisher","DOI":"10.1101\/gr.233866.117"},{"key":"ref039","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.785644"},{"key":"ref040","unstructured":"KirklandJL (2023)\n                      ALSENLITE: An Open-Label Pilot Study of Senolytics for Alzheimer\u2019s Disease\n                      , Identifier NCT04785300. https:\/\/clinicaltrials.gov\/study\/NCT04785300."},{"key":"ref041","unstructured":"LipsitzL (2023)\n                      Senolytics to Alleviate Mobility Issues and Neurological Impairment in Aging\n                      , Identifier NCT05422885. https:\/\/clinicaltrials.gov\/study\/NCT05422885."},{"key":"ref042","unstructured":"Wake Forest University Health Sciences (2022)\n                      Phase II Clinical Trial to Evaluate the Safety and Feasibilityof Senolytic Therapy in Alzheimer\u2019s Disease\n                      , Identifier NCT04685590. https:\/\/clinicaltrials.gov\/study\/NCT04685590."},{"key":"ref043","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.14506.1"},{"key":"ref044","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70299-6"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-230465","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JAD-230465","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-230465","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:09:20Z","timestamp":1777370960000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JAD-230465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,30]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,2,13]]}},"alternative-id":["10.3233\/JAD-230465"],"URL":"https:\/\/doi.org\/10.3233\/jad-230465","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,30]]}}}